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CASE STUDY
Familial Medullary Thyroid Carcinoma
Associated with Cutaneous Lichen Amyloidosis
Amy E. Rothberg,1 Victoria M. Raymond,2 Stephen B. Gruber,2 and James Sisson3
Background: This is a report of a patient with a novel genotype–phenotype relationship of a c804 mutation of the
RET proto-oncogene manifesting as medullary thyroid carcinoma (MTC) and cutaneous lichen amyloidosis (CLA).
Summary: Clinical data were obtained for patient appearance and laboratory results. Analyzed were histopathology
of the skin lesion and thyroid gland, genetic mutation, and family pedigree. Skin histology and histochemistry were
consistent with CLA. Serum calcitonin levels were moderately elevated. Thyroid histology demonstrated a 4 mm
focus of MTC. Measurements of serum parathormone, calcium, and plasma metanephrines were normal. DNA
analysis demonstrated a mutation in codon 804 of the RET proto-oncogene resulting in a Valine to Methionine
(V804M) substitution. Genetic testing in two siblings revealed the same mutation.
Conclusions: This is the first description of a patient with CLA not associated with a mutation in codon 634. The
patient is one of the few with a V804M mutation in whom the clinical expression did not fully conform to the
definition of familial MTC.
Introduction
Cutaneous lichen amyloidosis (CLA) is an uncommonbut recognized component of the multiple endocrine
neoplasia 2A syndrome (MEN 2A) (1,2). This clinical syn-
drome has previously been observed only in patients with
mutations in codon 634 (c634) of the RET proto-oncogene (3,4).
Familial medullary thyroid carcinoma (FMTC) has been de-
fined as presence of MTC in families who do not develop the
other features of MEN 2A (3,5). Mutations in c804 with me-
thionine substituted for valine (V804M) have regularly been
reported in association with FMTC (6–14) with the exception
of two reports of V804M mutation associated with pheochro-
mocytoma (15,16) and two with hyperparathyroidism (17,18).
However, the nonspecific clinical appearance of CLA may
obscure its diagnosis, and because the MTC of FMTC is often
indolent, CLA may elude diagnosis for decades, particularly
in patients who, with a RET mutation of V804M, usually de-
velop MTC in later life. We report a patient with CLA who
otherwise appears to exhibit FMTC, and in whom the RET
mutation of V804M was found.
Case Report
In 2008, a 51-year-old woman had endured an intensely,
but episodically pruritic, patch in the interscapular area of her
left back for over 10 years. In 2000, a dermatologist made the
diagnosis of macular amyloidosis secondary to repeated
scratching. A glucocorticoid cream provided minimal relief,
but no other medication was palliative. Her itch worsened
under periods of stress. In 2007, a second dermatologist
biopsied the lesion; the histology was interpreted as consis-
tent with cutaneous amyloidosis. An extensive investigation
for systemic amyloidosis followed and included a compre-
hensive metabolic profile with serum calcium, complete blood
cell count analysis, C-reactive protein, serum and urine pro-
tein electrophoreses, abdominal CT, echocardiography, eso-
phagogastroduodenoscopy, and colonoscopy with biopsies.
No abnormality was uncovered. The clinical and histological
appearances suggested CLA, and a genetic evaluation fol-
lowed (see Results).
In 1991, she developed invasive lobular carcinoma of the
breast: ER=PRþ, ([] for 0=14 lymph nodes sampled); re-
mission has persisted after lumpectomy, chemotherapy, and
external beam irradiation.
Her blood pressure and heart rate were within normal
limits. Her thyroid gland neither was enlarged nor exhibited
palpable nodules. She had no lymphadenopathy. In the left
interscapular area at the T2–T6 level was a hyperpigmented,
macular lesion.
Results
The location of the patient’s CLA is shown in Figure 1.
Clinically, it appeared as a brownish macule with discrete
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areas of excoriation. The histologic pattern demonstrated
characteristic features of the disorder, including mild acan-
thosis and hyperkeratosis. Within the superficial papillary
dermis and immediately beneath the dermal–epidermal
junction, there were homogenous eosinophilic deposits and
also numerous scattered melanophages (Fig. 2A). Insufficient
biopsy material prevented staining for amyloid. Repeat bi-
opsy stained with hematoxylin and eosin confirmed the
presence of amyloid (Fig. 2B).
DNA sequence analysis was performed to test for the
presence of a mutation in exons 10, 11, 13, 14, 15, and 16 of the
RET proto-oncogene and detected a mutation in exon 14:
2410G>A (GTC>ATG) giving a substitution of methionine
for valine: V804M. With this information, additional tests
were ordered. Levels of free fractionated plasma metane-
phrines were normal: normetanephrine 0.74 nmol=L (<0.90)
and metanephrine 0.34 nmol=L (<0.50). Intact serum para-
thyroid hormone was 33 pg=mL and normal; corresponding
calcium was 9.5 mg=dL.
In early 2008, basal serum calcitonin level was 31 pg=mL
(normal <13). Five and 7 months later, calcitonin levels were
47 and 48 pg=mL, respectively (normal <8). Thyroid ultraso-
nography depicted a normal-sized, mildly heterogeneous
thyroid gland containing, in the right lobe, a superior hy-
poechoic nodule measuring 234 mm, and, in the left lobe,
two small cystic nodules, 445 mm and 367 mm.
A total thyroidectomy with central neck compartment
dissection excised a 0.4 cm focus of medullary carcinoma re-
stricted to the left lobe of her thyroid gland (Fig. 3); lymph
nodes showed no metastasis. Her carcinoma was stage I.
Postoperative calcitonin level was <5 pg=mL, and expected
basal value <8 pg=mL.
The pedigree of the family is shown in Figure 4. Genetic
testing of the patient’s 40-year-old sister and 61-year-old
brother disclosed the same mutation, but, on careful exami-
nation, neither had skin changes. The brother’s calcitonin
level was moderately elevated at 40 pg=mL; the sister’s cal-
citonin level was within normal limits; neither has undergone
ultrasonography of the neck, and each is undecided about
prophylactic thyroidectomy. The patient’s mother is living at
age 81 years; she has had a single colonic polyp but is other-
wise in good health. The mother refused evaluation, but she
denies skin abnormalities. The patient’s other four siblings do
not wish to be tested.
There are four living maternal uncles who are in their 70s
and in good health; one maternal uncle died at age 70 years.
There are four living maternal aunts in good health. Her
maternal grandmother died at age 80 years and had history of
diabetes, and her maternal grandfather died young of an
unknown cause. Her father died at age 60 years of mesothe-
lioma; he had worked in a foundry. She has three paternal
aunts who were diagnosed with breast cancer in their 50s or
60s. These family members have not been examined, but here
is no history of skin disorder or thyroid disease. Con-
sanguinity was absent.
FIG. 1. Cutaneous lichen amyloidosis is seen extending
from the midline to the left. Inspection showed excoriations,
but otherwise a smooth surface. Color images available
online at www.liebertonline.com=thy.
FIG. 2. Photomicrographs of the patient’s skin lesion. (A)
First skin biopsy 200magnification portrays mild acantho-
sis and hyperkeratosis. Within the superficial papillary der-
mis, immediately beneath the dermal–epidermal junction,
there were homogenous eosinophilic deposits. There were
also numerous scattered melanophages. (B) Second biopsy
400 magnification, stained with hematoxylin and eosin,
revealing small globular deposits of amyloid in the papillary
dermis (arrow). Color images available online at www
.liebertonline.com=thy.
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Discussion
The characteristic features of CLA—pruritic symptoms
over years, anatomic location, and histologic changes in the
skin (19–22)—were present in our patient. She appears to be
the first to manifest CLA with a RET mutation other than c634
(3,4), and the genotype–phenotype relationship of V804M
must now include CLA.
Pruritus is usually the first manifestation of CLA; this is
in contradistinction to ‘‘friction amyloidoses’’ in which the
scratching and hyperpigmentation occur before the pruritus
(19,22,23). The rash occurs in the area of repeated scratching
and is located in the upper back at either or both interscapular
regions. Familial CLA has been described, but in this disorder,
the skin disease involves the arms and legs, and patients do
not manifest RET mutations (24). In a selected series reported
by Robinson (22), 31 of 44 patients had MTC and CLA. The
lesions occurred predominantly on the upper back on the
right side extending to the midline or bilateral extending
across the midline (19,20,22). Age of onset occurred usually
before 20 years, with the median being 13 years (22) and, in
each of two series of patients, the oldest age of first awareness
was 26 years (20,22). Yet, in one of nine patients from three
families, CLA was first noticed at age 52 years (19). Thirty of
the 31 patients presented with CLA before the diagnosis of
MEN 2A (22).
Scratching appears to play an important role in the path-
ogenesis of cutaneous amyloidosis by causing epidermal cell
damage that leads to filamentous degeneration of keratino-
cytes, subsequent apoptosis, and conversion of filamentous
masses into amyloid material (23). The neural crest cells,
implicated in embryological development of the adrenal
medulla and parafollicular C cells, are also involved in the
embryogenesis of the thoracic sensory fibers and their im-
pulses (25), a pattern that may explain the itch and subse-
quent scratch cycle predating other stigmata of the disorder.
Whereas amyloid has been an almost invariable component in
FIG. 3. Photomicrograph of medullary carcinoma consist-
ing of nests of neuroendocrine cells with abundant granular
cytoplasm and round to oval nuclei. A few bands of eosin-
ophilic amyloid stroma are present. Original magnification,
200. Tumor diameter was 4 mm. Color images available
online at www.liebertonline.com=thy.
FIG. 4. Pedigree chart. Pedigree of the patient (arrowhead). The appearances of the RET mutation V804M (þ) and of cancers
(breast, medullary thyroid, and lung) are shown. The number of family members in generation II was large, and, for clarity in
presentation, condensed: at the far left there were three males and one female, and at the far right there were four females and
two males, each of whom was unaffected by cancer. Genetic analysis for V804M had been performed only in three members
in generation III.
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the histologic picture of CLA, it may not be found in some
biopsy specimens (23,26).
FMTC is defined as MTC without other components of
MEN 2A, and the usual chronology is a later in life onset and
indolent progression. A number of RET mutations underlie
FMTC and have appeared in exons 10, 13, 14, and 15 (3,7) and
11 (3). Most patients with a V804M mutation have manifested
the FMTC pattern, but a few, aged 54–55 years and exhibiting
small MTC tumor(s), had features of MEN 2A; two presented
with hyperparathyroidism (17,18); two exhibited pheochro-
mocytomas, unilateral adrenal tumor in one (15), and bilateral
adrenal pheochromocytomas in the other (16). In patients
with MEN 2A, hyperparathyroidism and pheochromocyto-
mas generally appear chronologically after MTC (4). The
commonly late onset of MTC in patients with the V804M
mutation may obscure any predilections for hyperparathy-
roidism and pheochromocytomas. Our patient is the first with
V804M to express the extra-thyroidal feature of CLA; thus,
she does not conform to the strict criteria of FMTC. Other RET
mutations that present as FMTC also appear as MEN 2A.
Many families with C634Y have the multiple tumors of MEN
2A, while others present only FMTC (3). Although c804 has
generally appeared as FMTC, members of one family with
V804L mutation also exhibited pheochromocytomas (27).
In keeping with the usual pattern of FMTC, the MTC aris-
ing from V804M tends to appear in later years; in one series
the mean age was 54 years (7). The carcinomas tended to be
confined to the thyroid, but lymph node metastases have
occurred (7,8,10,12,13,15). Nevertheless, a patient with a
mutation in c804 (precise mutation not stated) developed
MTC at age 7 years (13), and one with the V804M mutation
developed MTC at 6 years and died at age 12 years (12). As in
our patient, basal calcitonin levels may be elevated at a time
when there is only C-cell hyperplasia or little evidence of
carcinoma (8,12).
It is possible that CLA has been overlooked in many pa-
tients. Symptoms may be mild (19) and the lesion itself is not
pathognomonic. Moreover, in patients with a V804M muta-
tion as in our patient, the MTC may be clinically unapparent,
and the genetic abnormality itself concealed. The genetic basis
for CLA remains obscure; it does not appear to be related to
the location of the codon; c634 is in the extracellular, cysteine-
rich domain, and c804 is in the intracellular, tyrosine-rich
domain (4,28).
In summary, we present a patient who exhibited a novel
genotype–phenotype relationship: V804M and CLA. Her
clinical appearance highlights that cutaneous disorders may
be the earliest sign of malignancy. CLA in the interscapular
area should prompt a search for MTC and MEN 2A. In ad-
dition, the patient is one of the few with the V804M mutation
that is not expressed as FMTC.
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